Piombino Dese (Padua), Italy, July 30, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, announced that liraglutide-based combination products incorporating its proprietary Alina® pen injector platform have received marketing authorizations in multiple European countries. The approvals relate to finished combination products held by the respective Marketing Authorization Holders.
The authorized products include Alina® 30, developed for liraglutide-based diabetes therapies, and Alina® 50, designed for weight management applications. Both are part of the Alina® variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1 and other injectable therapies.
Alina® features a dial-a-dose mechanism with visual, audible and tactile feedback during dose selection and injection, and is compatible with ISO standard 3 mL glass cartridges. The platform is designed to support manufacturing scalability and integration into existing pharmaceutical fill-and-finish and final assembly processes.
“We are pleased to see Alina® incorporated into liraglutide-based therapies that have received marketing authorizations in multiple European markets,” said Michele Monico, President of Drug Delivery Systems & In Vitro Diagnostics at Stevanato Group. “This achievement reflects our commitment to supporting customers from development through commercialization. As demand for diabetes and weight management treatments continues to grow, we are proud to provide drug delivery solutions that can help expand patient access to these therapies.”
The approvals come as injectable therapies continue to gain importance, driven by the growth of GLP-1 treatments and the increasing adoption of self-administration. Through its proprietary device portfolio—including Alina® (variable-dose pen injector), Deora™ (fixed-dose pen injector), Aidaptus® (autoinjector) and Vertiva® (on-body delivery system)—Stevanato Group continues to strengthen its drug delivery offering for pharmaceutical and biotechnology companies developing next-generation therapies.
Manufactured within Stevanato Group’s Drug Delivery Systems operations, Alina® leverages the company’s expertise in pharmaceutical glass containers, engineering technologies, analytical services and device manufacturing. The platform has been developed as a flexible, production-ready solution capable of supporting commercial-scale deployment.
“Drug delivery systems are becoming increasingly strategic to the success of injectable therapies,” Monico added. “The rapid growth of biologics, GLP-1 therapies and self-administration is reshaping pharmaceutical product development and commercialization. Demand is increasing for integrated solutions that combine device innovation, manufacturing expertise and supply chain reliability. We believe our portfolio and end-to-end capabilities position Stevanato Group to support this evolution.”
Founded in 1949, Stevanato Group is a leading global provider of integrated drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, supporting customers across the entire drug life cycle from development to commercialization.
